Skip to content

Tsuyoshi Goromaru

3 papers in the library · publishing 1990

Papers

Sort Most recent Most cited

Reduction of in vivo binding of [3H]paroxetine in mouse brain by 3,4-methylenedioxymethamphetamine.

Neuropharmacology July 1990 Kenji Hashimoto, Tsuyoshi Goromaru

The effects of 3,4-methylenedioxymethamphetamine (MDMA) on the in vivo binding of [3H]paroxetine, a potent and selective 5-hydroxytryptamine (5-HT; serotonin) uptake inhibitor, in the brain of the mouse were studied. The distribution of radioactivity in the brain of the mouse, after intravenous administration of [3H]paroxetine, was significantly altered by pretreatment with MDMA (15 mg/kg,...

Synthesis of racemic, S(+)‐ and R(‐)‐N‐[methyl‐3H]3,4‐methylenedioxymethamphetamine

Journal of Labelled Compounds and Radiopharmaceuticals April 1, 1990 Kenji Hashimoto, Katsumi Hirai, Tsuyoshi Goromaru

AbstractThe synthesis of 3,4‐methylenedioxymethamphetamine(MDMA), a serotonergic neurotoxin, labeled with tritium is described. Labeling was accomplished by N‐alkylation of the free base of the corresponding desmethyl compound using [3H]methyl iodide. The compound was purified by preparative HPLC. The radiochemical yield was about 60% based on [3H]methyl iodide. The radiochemical purity was...

Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine.

Fundamental & clinical pharmacology 1990 K Hashimoto, T Goromaru

3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a known neurotoxin to 5-hydroxytryptamine (5-HT; serotonin) nerve terminals. It has recently been demonstrated that [3H]6-nitroquipazine is a new radioligand for studying the 5-HT transport system in brain. Therefore, we examined the effects of repeated systemic administration (10 mg/kg ip, twice daily for 3 d) of MDMA on...